Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Authors

Matthew J. Barth
Jessica Hochberg, New York Medical CollegeFollow
Lauren Harrison, New York Medical CollegeFollow
Stanton Goldman
Allyson Flower, New York Medical CollegeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

9-2018

DOI

10.1111/bjh.15536

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Barth, M. J., Hochberg, J., Harrison, L., Goldman, S., Flower, A., & Cairo, M. S. (2018). Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma. British Journal of Haematology, 182 (Suppl. 1), 48-49. https://doi.org/10.1111/bjh.15536